Investors might want to bet on Mind Medicine (MindMed) Inc. (MNMD) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following y ...

Company Overview - Peapack-Gladstone (PGC) shares increased by 6% to $26.52 in the last trading session, following a significant volume of trading, contrasting with an 11.8% loss over the past four weeks [1][2] - The stock's recent rally was influenced by a broader market surge, particularly due to President Donald Trump's announcement of a 90-day tariff pause for non-retaliating nations, which positively impacted investor sentiment [2] Earnings and Revenue Expectations - Peapack-Gladstone is projected to report quarterly earnings of $0.54 per share, reflecting a year-over-year increase of 12.5% [2] - Expected revenues for the upcoming quarter are $63.4 million, representing a 19.4% increase compared to the same quarter last year [2] Stock Performance and Trends - The consensus EPS estimate for Peapack-Gladstone has remained stable over the last 30 days, indicating no recent revisions in earnings estimates, which typically correlates with stock price movements [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [4] Industry Context - Peapack-Gladstone operates within the Zacks Banks - Northeast industry, where Midland States Bancorp (MSBI) also resides, having closed 4.8% higher at $16.46, but with a -13.8% return over the past month [4] - Midland States Bancorp's consensus EPS estimate has remained unchanged at $0.52, indicating a -1.9% change compared to the previous year, and it currently holds a Zacks Rank of 5 (Strong Sell) [5]